News | July 31, 2023
Biogen to acquire Reata Pharmaceuticals
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Aurobindo will respond to the US FDA within the stipulated timelines
This product would be manufactured at Lupin's Nagpur facility in India
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Subscribe To Our Newsletter & Stay Updated
